Project Grant K08CA312394
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $348K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $659,201 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on the integrated stress response in glioblastoma pathogenesis and response to therapy. The funded research investigates how glioma stem cells survive and proliferate within the hostile glioblastoma microenvironment through adaptive stress response mechanisms. The work focuses on the...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Cancer Institute awarded Yale University $149,190 under the Cancer Research Manpower program (CFDA 93.398) on January 15, 2026, to support research investigating the role of N6-methyladenosine (M6A) in the development of drug resistance in glioblastoma. The research characterizes molecular mechanisms by which M6A, the most prevalent internal RNA modification in eukaryotic messenger RNA, regulates glioblastoma pathogenesis and explores how manipulation of M6A regulation may improve...
- The National Cancer Institute awarded the Trustees of Boston University $110,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research defining the landscape of whole-genome doubling across mammalian tissues. The recipient will use a transgenic cell-cycle reporter mouse model to identify, purify, and manipulate whole-genome doubling (WGD) cells from murine tissues. The research comprises two aims: quantifying how WGD-positive cells accumulate with...